There are currently 130 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Mechanisms of Rumination Change in Adolescent Depression
NCT03859297
Recruiting
This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these changes in habits and brain connectivity can reduce the risk for recurrence of depression in the next two years.
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
06/25/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio +2 locations
Conditions: Major Depressive Disorder, Mood Disorders
Register for Updates
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
NCT05950711
Recruiting
The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2023
Locations: Harding Hospital, Columbus, Ohio
Conditions: Major Depressive Disorder
Register for Updates
Using MHealth to Improve Adherence and Reduce Blood Pressure in Individuals with Hypertension and Mood Disorders
NCT04675593
Recruiting
This proposed 2-stage randomized controlled trial (RCT) will evaluate a personalized patient-centered adherence intervention iTAB-CV + Self-Monitoring (iTAB-CV + SM) vs. Self-Monitoring (SM) alone in poorly adherent hypertensive persons with BD or MDD. This practical, technology-facilitated intervention has potential to improve adherence to antihypertensive medication and reduce SBP among high-risk individuals. The intervention is suitable for primary care or mental health settings and has poten... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
09/09/2024
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Bipolar Disorder, Non-Adherence, Medication, Hypertension, Major Depressive Disorder
Register for Updates
Psilocybin for Treatment-Resistant Depression
NCT06230757
Recruiting
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
03/25/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator site, Huntsville, Alabama +149 locations
Conditions: Major Depressive Disorder
Register for Updates
Defining Neurobiological Links Between Substance Use and Mental Illness
NCT05538910
Recruiting
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brai... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/25/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Major Depressive Disorder, Substance Use Disorder, Normal Physiology
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator Site, Cerritos, California +65 locations
Conditions: Major Depressive Disorder
Register for Updates
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
NCT05536414
Recruiting
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD). The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: Yuma CNS Research, Yuma, Arizona +61 locations
Conditions: Major Depressive Disorder
Register for Updates
Natural History of Depression, Bipolar Disorder and Suicide Risk
NCT06462196
Recruiting
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medica... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Register for Updates
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335
Recruiting
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objective: Main Study: To study the effects of ketamine in treating depression. Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry. To study how ketamine effects the brain. This... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer, Major Depressive Disorder, Depression
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/20/2025
Locations: IMA Clinical Research Phoenix, Phoenix, Arizona +18 locations
Conditions: Major Depressive Disorder
Register for Updates
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
NCT06897670
Recruiting
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Register for Updates